Open Access Green as soon as Postprint is submitted to ZB.
Multimodal molecular imaging of integrin αvβ3 for in vivo detection of pancreatic cancer.
J. Nucl. Med. 55, 446-451 (2014)
UNLABELLED: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. Late detection of then nonresectable or metastasized tumors emphasizes the need for novel imaging approaches. Here, we report on so far nonexploited potentials of αvβ3 integrin-targeted molecular imaging technologies for detection of PDAC using genetically engineered mouse models. METHODS: Immunohistochemistry and Western blot were used for characterization of αvβ3 expression in murine and human PDAC. We applied IntegriSense 680 fluorescence molecular tomography, intraoperative fluorescence imaging, and (68)Ga-NODAGA-RGD PET for αvβ3 integrin molecular in vivo imaging of spontaneous PDAC occurring in Ptf1a(+/Cre);Kras(+/LSL-G12D);p53(LoxP/LoxP) mice. (NODAGA is 1,4,7-triazacyclononane-1,4-bis[acetic acid]-7-[2-glutaric acid] and RGD is arginine-glycine-aspartic acid.) RESULTS: αvβ3 integrin is expressed in tumor cells of human and murine PDAC. IntegriSense fluorescence molecular tomography and (68)Ga-NODAGA-RGD PET enabled faithful visualization of PDAC. Furthermore, intraoperative optical imaging with IntegriSense 680 allowed good delineation of tumor borders. CONCLUSION: Imaging approaches targeting αvβ3 integrin expand the potential of molecular imaging for identification of αvβ3-positive PDAC with potential implications in early detection, fluorescence-guided surgery, and therapy monitoring.
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Fluorescence Molecular Tomography ; Genetically Engineered Mice ; Integrin αvβ3 ; Pancreatic Cancer ; Positron Emission Tomography; Ray Computed-tomography; Precursor Lesions; Tumor Xenografts; Ovarian-cancer; Cathepsin-e; Fluorescence; Expression; Mouse; Alpha-v-beta-3; Progression
Institute(s) Institute of Biological and Medical Imaging (IBMI)